KN 018Alternative Names: KN-018
Latest Information Update: 13 Jul 2016
At a glance
- Originator Alphamab
- Mechanism of Action CD80 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 13 Jul 2016 KN 018 is available for licensing as of 07 May 2015. http://www.alphamab.com/
- 07 May 2015 Preclinical trials in Autoimmune disorders in China (unspecified route)